tradingkey.logo

Fortrea Holdings Inc

FTRE
查看詳細走勢圖
17.700USD
-0.210-1.17%
收盤 12/24, 13:00美東報價延遲15分鐘
1.63B總市值
虧損本益比TTM

Fortrea Holdings Inc

17.700
-0.210-1.17%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.17%

5天

+9.33%

1月

+48.12%

6月

+233.33%

今年開始到現在

-5.09%

1年

-5.60%

查看詳細走勢圖

TradingKey Fortrea Holdings Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Fortrea Holdings Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名50/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價11.10。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Fortrea Holdings Inc評分

相關信息

行業排名
50 / 404
全市場排名
131 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 11 分析師
持有
評級
11.100
目標均價
-24.90%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Fortrea Holdings Inc亮點

亮點風險
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

Fortrea Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Fortrea Holdings Inc簡介

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
公司代碼FTRE
公司Fortrea Holdings Inc
CEOThakrala (Anshul)
網址https://www.fortrea.com/

常見問題

Fortrea Holdings Inc(FTRE)的當前股價是多少?

Fortrea Holdings Inc(FTRE)的當前股價是 17.700。

Fortrea Holdings Inc 的股票代碼是什麼?

Fortrea Holdings Inc的股票代碼是FTRE。

Fortrea Holdings Inc股票的52週最高點是多少?

Fortrea Holdings Inc股票的52週最高點是20.260。

Fortrea Holdings Inc股票的52週最低點是多少?

Fortrea Holdings Inc股票的52週最低點是3.970。

Fortrea Holdings Inc的市值是多少?

Fortrea Holdings Inc的市值是1.63B。

Fortrea Holdings Inc的淨利潤是多少?

Fortrea Holdings Inc的淨利潤為-328.50M。

現在Fortrea Holdings Inc(FTRE)的股票是買入、持有還是賣出?

根據分析師評級,Fortrea Holdings Inc(FTRE)的總體評級為持有,目標價格為11.100。

Fortrea Holdings Inc(FTRE)股票的每股收益(EPS TTM)是多少

Fortrea Holdings Inc(FTRE)股票的每股收益(EPS TTM)是-11.210。
KeyAI